Mecasermin

From WikiProjectMed
Jump to navigation Jump to search
Mecasermin
Names
Trade namesIncrelex
Other namesFK-780; recombinant human insulin-like growth factor-1; rhIGF-1; somatomedin-1
Clinical data
Main usesGrowth failure due to primary insulin-like growth factor-I deficiency[1]
Side effectsHeadache, low blood sugar, vomiting, lump at the site of injection, middle ear infection[2]
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
use
Subcutaneous injection
Typical dose0.04 to 0.12 mg/kg BID[2]
External links
AHFS/Drugs.comMonograph
US NLMMecasermin
Legal
License data
Legal status
Pharmacokinetics
Elimination half-life5.8 hours[3]
Chemical and physical data
FormulaC331H512N94O101S7
Molar mass7648.71 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Mecasermin, sold under the brand name Increlex, is medication used to treat growth failure in children due to primary insulin-like growth factor-I deficiency or lack of the gene for growth hormone.[1] It is also being look at for amyotrophic lateral sclerosis.[1] It is given by injection under the skin.[1]

Common side effects include headache, low blood sugar, vomiting, lump at the site of injection, and middle ear infection.[2] Other side effects may include enlarged tonsils, intracranial hypertension, and slipped capital femoral epiphysis.[1] It is a recombinant form of human insulin-like growth factor-1 (rhIGF-1).[1]

Mecasermin was approved for medical use in the United States in 2005 and Europe in 2007.[1][2] In the United States 400 mg costs about 54,000 USD as of 2021.[4] This amount in the United Kingdom costs the NHS about £24,000.[5]

Medical uses

It may be used in those 2 to 18 years old.[2]

Dosage

It is started at 0.04 mg/kg twice per day and may be increased up to 0.12 mg/kg twice per day.[2]

Chemistry

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[3]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[6] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[6]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Mecasermin Monograph for Professionals". Drugs.com. Retrieved 14 November 2021.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 "Increlex". Retrieved 15 November 2021.
  3. 3.0 3.1 "INCRELEX® (mecasermin [rDNA origin] injection) Highlights of Prescribing Information" (PDF). U.S. Food and Drug Administration.
  4. "Increlex Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 15 November 2021.
  5. "Mecasermin". NICE. Retrieved 15 November 2021.
  6. 6.0 6.1 "IPLEXTM (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration.

External links

External sites:
Identifiers: